T-cell receptor clonotypes shared among ankylosing spondylitis patients
AssigneeSequenta, Inc.
InventorsMalek Faham, Victoria Carlton, Martin Moorhead, Jianbiao Zheng, Thomas Asbury
Life of this patent
Estimating the term…
Abstract
The invention includes a method for determining the disease status of an individual suffering from ankylosing spondylitis by monitoring the individual's T-cell repertoire for the presence and/or level of clonotypes encoding T-cell receptor chains with segments identical to and/or related to the peptide LCASSLEASGSSYNEQFFGPGTRLTV (SEQ ID NO: 1) or the peptide VYFCASSDSSGSTDTQYFGPGTRLTV (SEQ ID NO: 2). The invention also includes therapeutic antibodies specific for these peptides for ameliorating the effects of ankylosing spondylitis.
Claims11
A method for determining a disease status of a patient suffering from, or suspected of suffering from, ankylosing spondylitis, the method comprising the steps of:
- (a) obtaining a sample from the patient comprising T-cells;
- (b) amplifying molecules of nucleic acid from the T-cells of the sample, the molecules of nucleic acid comprising recombined DNA sequences from T-cell receptor genes;
- (c) sequencing the amplified molecules of nucleic acid to form a clonotype profile;
- (d) determining from the clonotype profile a presence, an absence and/or a level of clonotypes encoding segments of a T-cell receptor at least seventy percent homologous to a segment in the group consisting of LCASSLEASGSSYNEQFFGPGTRLTV (SEQ ID NO:
- 1) and VYFCASSDSSGSTDTQYFGPGTRLTV (SEQ ID NO:
- 2);
- and
- (e) correlating the presence, absence and/or level of such clonotypes with a status of ankylosing spondylitis in the patient.
A method for determining a disease status of a patient suffering from, or suspected of suffering from, ankylosing spondylitis, the method comprising the steps of:
- determining in a clonotype profile of a tissue sample of the patient the presence, absence and/or quantity of clonotypes encoding segments of a T-cell receptor at least ninety percent homologous to a segment in the group consisting of LCASSLEASGSSYNEQFFGPGTRLTV (SEQ ID NO:
- 1) and VYFCASSDSSGSTDTQYFGPGTRLTV (SEQ ID NO:
- 2);
- correlating a presence or an elevation in a level of such clonotypes to a presence of ankylosing spondylitis in the patient;
- and
- treating the patient with an effective amount of a medication selected from the group consisting of an anti-inflammatory drug, a disease modifying anti-rheumatic drug (DMARD), and a TNFα blocker.
An isolated antibody specific for an amino acid segment of a T cell receptor, the amino acid segment being selected from the group consisting of LCASSLEASGSSYNEQFFGPGTRLTV (SEQ ID NO:
- 1) and any 6 to 20 amino acid segment thereof and VYFCASSDSSGSTDTQYFGPGTRLTV (SEQ ID NO:
- 2) and any 6 to 20 amino acid segment thereof.
(canceled)
Dependencies are inferred from the claim text.